Cynata Therapeutics Ltd (ASX:CYP) CEO Dr Kilian Kelly speaks with Proactive soon after announcing the company has initiated the first site in the USA in its Phase 2 clinical trial of CYP-001, in patients with High-Risk acute Graft versus Host Disease (HR-aGvHD). The trial opened for recruitment in Australia in August 2023. Cynata Therapeutics is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™ - a proprietary therapeutic stem cell platform technology.
Cynata Therapeutics opens first US site in Phase 2 CYP-001 trial
